Advertisement
Screener

Merck & Co., Inc. (MRK) Graph

MRK Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $16.61B; Cost of revenue $4.39B; Research and development $9.74B; Selling, general and administrative $2.90B.
  • 2026-03-31: Revenue $16.29B; Cost of revenue $4.20B; Research and development $12.59B; Selling, general and administrative $2.70B.
  • 2025-12-31: Revenue $16.40B*; Cost of revenue $5.55B*; Research and development $3.89B*; Selling, general and administrative $2.90B*.
  • 2025-09-30: Revenue $17.28B; Cost of revenue $3.85B; Research and development $4.23B; Selling, general and administrative $2.63B.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

MRK revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Corporate Non Segment$72.00MOperating Segments$16.54BRevenue$16.61BCost of revenue$4.40BOther income, net-$99.00MResearch & development$9.74BSelling, general& administrative$2.90BPre-tax income-$683.00MIncome tax$654.00M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

MRK revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Asia Pacific$820.00MLatin America$875.00MEMEA$3.92BNon Us$7.24BOther Countries$640.00MCN$408.00MJP$577.00MUS$9.37BRevenue$16.61BCost of revenue$4.40BOther income, net-$99.00MResearch & development$9.74BSelling, general& administrative$2.90BPre-tax income-$683.00MIncome tax$654.00M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$16.61B$4.39B$9.74B$2.90B$654.00M-$1.33B
2026-03-31$16.29B$4.20B$12.59B$2.70B$709.00M-$4.24B
2025-12-31$16.40B*$5.55B*$3.89B*$2.90B*$458.00M*$2.96B*
2025-09-30$17.28B$3.85B$4.23B$2.63B$958.00M$5.79B
2025-06-30$15.81B$3.56B$4.05B$2.65B$571.00M$4.43B
2025-03-31$15.53B$3.42B$3.62B$2.55B$818.00M$5.08B
2024-09-30$16.66B$4.08B$5.86B$2.73B$929.00M$3.16B
2024-06-30$16.11B$3.75B$3.50B$2.74B$545.00M$5.46B
2024-03-31$15.78B$3.54B$3.99B$2.48B$903.00M$4.76B
2023-09-30$15.96B$4.26B$3.31B$2.52B$870.00M$4.75B
2023-06-30$15.04B$4.02B$13.32B$2.70B$637.00M-$5.97B
2023-03-31$14.49B$3.93B$4.28B$2.48B$825.00M$2.82B
2022-09-30$14.96B$3.93B$4.40B$2.52B$330.00M$3.25B
2022-06-30$14.59B$4.22B$2.80B$2.51B$538.00M$3.94B
2022-03-31$15.90B$5.38B$2.58B$2.32B$554.00M$4.31B
2021-09-30$13.15B$3.45B$2.44B$2.34B$695.00M$4.57B
2021-06-30$11.40B$3.10B$4.32B$2.28B$503.00M$1.54B
2021-03-31$10.63B$3.20B$2.41B$2.19B$238.00M$3.18B
2020-09-30$10.93B$3.01B$3.35B$2.06B$380.00M$2.94B
2020-06-30$9.35B$2.75B$2.08B$2.08B$396.00M$3.00B
2020-03-31$12.06B$3.31B$2.21B$2.56B$619.00M$3.22B
2019-09-30$12.40B$3.99B$3.20B$2.59B$440.00M$1.90B
2019-06-30$11.76B$3.40B$2.19B$2.71B$615.00M$2.67B
2019-03-31$10.82B$3.05B$1.93B$2.42B$205.00M$2.92B
2018-09-30$10.79B$3.62B$2.07B$2.44B$707.00M$1.95B
2018-06-30$10.46B$3.42B$2.27B$2.51B$370.00M$1.71B
2018-03-31$10.04B$3.18B$3.20B$2.51B$604.00M$736.00M
2017-09-30$10.32B$3.31B$4.41B$2.46B$251.00M-$56.00M
2017-06-30$9.93B$3.12B$1.78B$2.50B$488.00M$1.95B
2017-03-31(m)(m)$1.83B$2.47B$447.00M$1.55B
2016-09-30(m)(m)$1.66B$2.39B$699.00M$2.18B
2016-06-30(m)(m)$2.15B$2.46B$295.00M$1.21B
2016-03-31(m)(m)$1.66B$2.32B$494.00M$1.13B
2015-09-30(m)(m)$1.50B$2.47B$566.00M$1.83B
2015-06-30(m)(m)$1.67B$2.62B$119.00M$687.00M
2015-03-31(m)(m)$1.74B$2.60B$423.00M$953.00M
2014-09-30(m)(m)$1.66B$2.98B$648.00M$895.00M
2014-06-30(m)(m)$1.66B$2.97B-$142.00M$2.00B
2014-03-31(m)(m)$1.57B$2.73B$360.00M$1.71B
2013-09-30(m)(m)$1.66B$2.80B$375.00M$1.12B
2013-06-30(m)(m)$2.10B$3.14B$310.00M$906.00M
2013-03-31(m)(m)$1.91B$2.99B-$66.00M$1.59B
2012-09-30(m)(m)$1.92B$3.06B$455.00M$1.73B
2012-06-30(m)(m)$2.17B$3.25B$860.00M$1.79B
2012-03-31(m)(m)$1.86B$3.07B$740.00M$1.74B
2011-09-30(m)(m)$1.95B$3.34B$628.00M$1.69B
2011-06-30(m)(m)$1.94B$3.52B-$382.00M$2.02B
2011-03-31$11.58B(m)$2.16B$3.16B$658.00M$1.04B
2010-12-31$12.09B*(m)(m)(m)(m)(m)
2010-09-30$11.12B(m)$2.32B$3.19B$126.00M$342.00M
2010-06-30$11.35B(m)$2.18B$3.17B$461.00M$752.00M
2010-03-31$11.42B(m)$2.05B$3.22B$286.00M$299.00M
2009-09-30$6.05B$1.72B$1.25B$1.73B$1.62B$3.42B
2009-06-30$5.90B$1.62B$1.40B$1.73B$379.00M$1.56B
2009-03-31$5.39B(m)$1.22B$1.63B$327.20M$1.43B
2008-09-30$4.58B$1.74B$893.00M$1.66B$44.00M$614.00M
2008-06-30$4.92B$1.91B$906.00M$1.87B$40.00M$462.00M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$32.89B$8.59B$22.33B$5.60B$1.36B-$5.58B
2025-06-30$31.34B$6.98B$7.67B$5.20B$1.39B$9.51B
2024-06-30$31.89B$7.29B$7.49B$5.22B$1.45B$10.22B
2023-06-30$29.52B$7.95B$17.60B$5.18B$1.46B-$3.15B
2022-06-30$30.49B$9.60B$5.37B$4.83B$1.09B$8.25B
2021-06-30$22.03B$6.30B$6.73B$4.47B$741.00M$4.72B
2020-06-30$19.64B$5.58B$4.26B$4.28B$891.00M$6.22B
2019-06-30$22.57B$6.45B$4.12B$5.14B$820.00M$5.58B
2018-06-30$20.50B$6.60B$5.47B$5.02B$975.00M$2.44B
2017-06-30$19.36B$6.17B$3.61B$4.97B$935.00M$3.50B
2016-06-30(m)(m)$3.81B$4.78B$789.00M$2.33B
2015-06-30(m)(m)$3.41B$5.23B$542.00M$1.64B
2014-06-30(m)(m)$3.24B$5.71B$218.00M$3.71B
2013-06-30(m)(m)$4.01B$6.13B$244.00M$2.50B
2012-06-30(m)(m)$4.03B$6.32B$1.60B$3.53B
2011-06-30(m)(m)$4.09B$6.69B$276.00M$3.07B
2010-06-30$22.77B(m)$4.23B$6.40B$746.00M$1.05B
2009-06-30$11.29B$3.02B$2.62B$3.36B$706.20M$2.98B
2008-06-30$9.58B$4.04B$1.79B$3.55B$89.00M$775.00M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$48.61B$10.83B$11.90B$7.83B$2.35B$15.29B
2024-09-30$48.54B$11.37B$13.35B$7.95B$2.38B$13.37B
2023-09-30$45.48B$12.21B$20.90B$7.70B$2.33B$1.59B
2022-09-30$45.45B$13.53B$9.77B$7.36B$1.42B$11.50B
2021-09-30$35.18B$9.75B$9.18B$6.80B$1.44B$9.29B
2020-09-30$30.57B$8.59B$7.61B$6.34B$1.27B$9.16B
2019-09-30$34.97B$10.44B$7.32B$7.73B$1.26B$7.49B
2018-09-30$31.30B$10.22B$7.54B$7.46B$1.68B$4.39B
2017-09-30$29.69B$9.47B$8.02B$7.43B$1.19B$3.44B
2016-09-30(m)(m)$5.47B$7.17B$1.49B$4.51B
2015-09-30(m)(m)$4.91B$7.70B$1.11B$3.46B
2014-09-30(m)(m)$4.90B$8.68B$865.00M$4.60B
2013-09-30(m)(m)$5.67B$8.93B$618.00M$3.62B
2012-09-30(m)(m)$5.94B$9.39B$2.06B$5.26B
2011-09-30(m)(m)$6.05B$10.03B$904.00M$4.76B
2010-09-30$33.89B(m)$6.55B$9.59B$872.00M$1.39B
2009-09-30$17.33B$4.74B$3.87B$5.09B$2.33B$6.41B
2008-09-30$14.15B$5.78B$2.68B$5.21B$133.00M$1.39B

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$65.01B$16.38B$15.79B$10.73B$2.80B$18.25B
2024-12-31$64.17B$15.19B$17.94B$10.82B$2.80B$17.12B
2023-12-31$60.12B$16.13B$30.53B$10.50B$1.51B$365.00M
2022-12-31$59.28B$17.41B$13.55B$10.04B$1.92B$14.52B
2021-12-31$48.70B$13.63B$12.24B$9.63B$1.52B$12.35B
2020-12-31$41.52B$13.62B$13.40B$8.96B$1.34B$7.07B
2019-12-31$39.12B$12.02B$9.72B$9.46B$1.56B$9.84B
2018-12-31$42.29B$13.51B$9.75B$10.10B$2.51B$6.22B
2017-12-31$40.12B$12.91B$10.34B$10.07B$4.10B$2.39B
2016-12-31$39.81B$14.03B$10.26B$10.02B$718.00M$3.92B
2015-12-31(m)(m)$6.70B$10.31B$942.00M$4.44B
2014-12-31(m)(m)$7.18B$11.61B$5.35B$11.92B
2013-12-31(m)(m)$7.50B$11.91B$1.03B$4.40B
2012-12-31(m)(m)$8.17B$12.78B$2.44B$6.17B
2011-12-31(m)(m)$8.47B$13.73B$942.00M$6.27B
2010-12-31$45.99B(m)$11.11B$13.13B$671.00M$861.00M
2009-12-31$27.43B(m)$5.84B$8.54B$2.27B$12.90B
2008-12-31$23.85B(m)$4.80B$7.38B$2.00B$7.81B
2007-12-31$24.20B(m)$4.88B$7.56B$95.30M$3.28B

Similar stocks

Stock NameCountryMarket CapPE Ratio
AbbVie Inc. (ABBV)United States$468.180B70.37
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60